Sfoglia per Autore ZAGAMI, PAOLA
What therapies are on the horizon for HER2 positive breast cancer?
2019 G. Viale, S. Morganti, E. Ferraro, P. Zagami, A. Marra, G. Curigliano
Antibody-drug conjugates in breast cancer : the chemotherapy of the future?
2020 E. Nicolò, P. Zagami, G. Curigliano
Pretreatment Blood Parameters Predict Efficacy from Immunotherapy Agents in Early Phase Clinical Trials
2020 C. Criscitiello, A. Marra, S. Morganti, P. Zagami, G. Viale, A. Esposito, G. Curigliano
Management of Cardiac Toxicity Induced by Chemotherapy
2020 D. Trapani, P. Zagami, E. Nicolò, G. Pravettoni, G. Curigliano
The rare entity of bilateral and unilateral neuroendocrine metastases to the breast: A case series and literature review
2020 P. Zagami, E. Kandaraki, G. Renne, F. Grimaldi, F. Spada, A. Laffi, N. Fazio
EGFR-TKI plus anti-angiogenic drugs in EGFR-mutated non–small cell lung cancer: A meta-analysis of randomized clinical trials
2020 F. Conforti, L. Pala, V. Bagnardi, C. Specchia, C. Oriecuia, A. Marra, P. Zagami, S. Morganti, P. Tarantino, C. Catania, F. de Marinis, P. Queirolo, T. de Pas
Systemic Treatment of Ductal Carcinoma In Situ of the Breast
2021 E. Crimini, C. Corti, M. Repetto, F. Giugliano, G. Antonarelli, P. Tarantino, P. Zagami, S. Morganti, E. Nicolo, J. Uliano, G. Curigliano
First line treatment of BRAF mutated advanced melanoma: Does one size fit all?
2021 F. Giugliano, E. Crimini, P. Tarantino, P. Zagami, J. Uliano, C. Corti, D. Trapani, G. Curigliano, P.A. Ascierto
Sex-based dimorphism of anticancer immune response and molecular mechanisms of immune evasion
2021 F. Conforti, L. Pala, E. Pagan, V. Bagnardi, T. De Pas, P. Queirolo, E. Pennacchioli, C. Catania, E. Cocorocchio, P.F. Ferrucci, M. Saponara, G. Orsolini, P. Zagami, E. Nicolo, F. De Marinis, G. Tortora, E. Bria, S. Minucci, H. Joffe, P. Veronesi, J. Wargo, R. Rosenthal, C. Swanton, A. Mantovani, R.D. Gelber, G. Viale, A. Goldhirsch, G. Giaccone
Seroconversion in patients with cancer and oncology health care workers infected by SARS-CoV-2
2021 A. Marra, D. Generali, P. Zagami, V. Cervoni, S. Gandini, S. Venturini, S. Morganti, R. Passerini, R. Orecchia, G. Curigliano
Pathological and clinical features of enteric adenocarcinoma of the thymus. A pooled analysis of cases from a reference center and systematic review of the literature
2021 F. Conforti, P. Tarantino, P. Trillo, L. Pala, P. Zagami, S. Pirola, B. Di Venosa, C. Catania, P. Queirolo, E. Pennacchioli, P. Della Vigna, G. Curigliano, T.M. De Pas
Body mass index, adiposity and tumour infiltrating lymphocytes as prognostic biomarkers in patients treated with immunotherapy: A multi-parametric analysis
2021 A. Esposito, A. Marra, V. Bagnardi, S. Frassoni, S. Morganti, G. Viale, P. Zagami, G.M. Varano, G. Buccimazza, F. Orsi, K. Venetis, L. Mazzarella, G. Viale, N. Fusco, C. Criscitiello, G. Curigliano
Characterization of low HER2 expressions in de-novo metastatic breast cancer
2021 P. Tarantino, E. Nicolo, P. Zagami, F. Giugliano, P. Aliaga, E. Crimini, C. Corti, J. Uliano, S. Morganti, L. Mazzarella, C. Criscitiello, A. Esposito, G. Curigliano
Clinical outcomes of patients with metastatic breast cancer enrolled in phase I clinical trials
2021 C. Criscitiello, A. Marra, S. Morganti, P. Zagami, S. Gandini, A. Esposito, G. Curigliano
Assessing predictors of tamoxifen nonadherence in patients with early breast cancer
2021 E. Montagna, P. Zagami, M.A. Masiero, K. Mazzocco, G. Pravettoni, E. Munzone
Fed or fasted state for oral therapies in breast cancer treatment? A comprehensive review of clinical practice recommendations
2021 E. Nicolò, D. Trapani, P.P.M. Berton Giachetti, P. Zagami, G. Curigliano
Avelumab plus axitinib in unresectable or metastatic type B3 thymomas and thymic carcinomas (CAVEATT): a single-arm, multicentre, phase 2 trial
2022 F. Conforti, P.A. Zucali, L. Pala, C. Catania, V. Bagnardi, I. Sala, P. Della Vigna, M. Perrino, P. Zagami, C. Corti, S. Stucchi, M. Barberis, E. Guerini-Rocco, B. Di Venosa, F. De Vincenzo, N. Cordua, A. Santoro, G. Giaccone, T.M. De Pas
Management of Patients with Cardiac Toxicity: The Point of View of the Oncologist
2022 P. Zagami, S. Morganti, P. Tarantino, G. Curigliano
Evolution of low HER2 expression between early and advanced-stage breast cancer
2022 P. Tarantino, S. Gandini, E. Nicolo, P. Trillo, F. Giugliano, P. Zagami, G. Vivanet, F. Bellerba, D. Trapani, A. Marra, A. Esposito, C. Criscitiello, G. Viale, G. Curigliano
Refining risk stratification in HR-positive/HER2-negative early breast cancer: how to select patients for treatment escalation?
2022 S. Morganti, A. Marra, E. Crimini, P. D'Amico, P. Zagami, G. Curigliano
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile